← Back to Search

Sleep Optimization for Type 1 Diabetes (SOPT Trial)

N/A
Recruiting
Led By Pamela Martyn-Nemeth, PhD
Research Sponsored by University of Illinois at Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adults aged 18-65 years
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from week. 6, 12, 24
Awards & highlights

SOPT Trial Summary

This trial found that the sleep intervention Sleep-Opt improved sleep and glycemic control in working-age adults with type 1 diabetes, which could lead to reduced development of diabetes complications and improved quality of life.

Who is the study for?
This trial is for adults aged 18-65 with type 1 diabetes who've had it for at least a year. They should have irregular sleep or get less than 6.5 hours of sleep on workdays, want to improve their sleep, and own a smartphone. It's not for those with recent severe hypoglycemia, night shift workers, pregnant women, insomnia sufferers, those on sleep meds, with renal issues or serious other diseases.Check my eligibility
What is being tested?
The study tests 'Sleep-Opt', an intervention combining wearable tech to track sleep patterns, phone coaching sessions and educational materials aimed at enhancing the quality of sleep and blood sugar control in people with type 1 diabetes.See study design
What are the potential side effects?
Since this trial focuses on lifestyle changes rather than medication there are no direct side effects like you'd expect from drugs; however participants may experience changes in sleeping habits as they adjust to new routines.

SOPT Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 65 years old.

SOPT Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from week. 6, 12, 24
This trial's timeline: 3 weeks for screening, Varies for treatment, and change from week. 6, 12, 24 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Glycemic control
Sleep duration
Sleep variability
Secondary outcome measures
Diabetes distress
Fatigue
Mood
+1 more

SOPT Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Sleep-OptExperimental Treatment1 Intervention
12-week intervention that includes self-monitoring, goal setting, motivational enhancement.
Group II: Healthy LivingActive Control1 Intervention
12-week intervention that includes weekly telephone contact, didactic content equal in time and attention to intervention group.

Find a Location

Who is running the clinical trial?

University of Illinois at ChicagoLead Sponsor
609 Previous Clinical Trials
1,559,165 Total Patients Enrolled
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
2,359 Previous Clinical Trials
4,314,448 Total Patients Enrolled
Pamela Martyn-Nemeth, PhDPrincipal Investigator - University of Illinois at Chicago
University of Illinois at Chicago
3 Previous Clinical Trials
75 Total Patients Enrolled

Media Library

Healthy Living Clinical Trial Eligibility Overview. Trial Name: NCT04506151 — N/A
Type 1 Diabetes Research Study Groups: Healthy Living, Sleep-Opt
Type 1 Diabetes Clinical Trial 2023: Healthy Living Highlights & Side Effects. Trial Name: NCT04506151 — N/A
Healthy Living 2023 Treatment Timeline for Medical Study. Trial Name: NCT04506151 — N/A
Type 1 Diabetes Patient Testimony for trial: Trial Name: NCT04506151 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experimental research open to individuals aged 55 and up?

"This clinical trial has an age restriction. The lower limit is 18 and the upper boundary for eligibility is 65 years old."

Answered by AI

How many participants are being included in this research effort?

"Affirmative. Clinicaltrials.gov lists this medical trial as actively recruiting, which began on January 19th 2021 and lastly edited on March 13th 2022. 144 participants are required to enter the study at a single locale."

Answered by AI

What goals are researchers hoping to achieve with this clinical trial?

"This medical investigation, to be assessed between the initial and six-week, twelve-week, and two year marks explores sleep duration as its primary endpoint. Secondary metrics include mood (as measured by CESD), diabetes distress (assessed through T1DSS) and fatigue adjudicated with PROMIS)."

Answered by AI

Are persons from the public eligible to be a part of this research endeavor?

"Affirmative. According to information available on clinicaltrials.gov, this medical trial is actively recruiting patients with the first posting date being January 19th 2021 and the most recent update occurring March 13th 2022. In total, 144 individuals are needed from a single centre."

Answered by AI

What are the eligibility requirements for participating in this research project?

"This medical trial requires 144 volunteers, who must meet the following criteria: between 18 and 65 years of age, diagnosed with type 1 diabetes mellitus, demonstrate habitual sleep variances (at least one hour in a week) or inadequate rest during work-/weekdays as recorded by an actigraphy watch, have a goal to improve their sleeping patterns and own a smartphone."

Answered by AI

Who else is applying?

What state do they live in?
Illinois
How old are they?
18 - 65
What site did they apply to?
University of Illinois Chicago
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

I've had issues sleeping since diagnosis that are impacting my glucose levels.
PatientReceived 1 prior treatment

How responsive is this trial?

Typically responds via
Phone Call
Email
Most responsive sites:
  1. University of Illinois Chicago: < 48 hours
Average response time
  • < 2 Days
~34 spots leftby Apr 2025